Summary

We use the most thorough and iterative research technique available, with a primary focus on offering the most precise market projections and research data content to help you develop previously unheard-of levels of business acumen. The company's primary methods for qualitative market assessments and market segmentation are top-down and bottom-up techniques. We take pride in our ability to use data triangulation to examine the market from three key angles: primary data mining, a specific statistical model and framework, and primary source data validation.

We carefully choose our original raw market data for analysis from a vast collection of data that has been compiled in our repository, as well as from sets of trustworthy and validated websites, analyst evaluations, news announcements, whitepapers, and reputable paid databases. Trade journals and in-depth surveys are used to collaborate on technical data and trends. Verified sources are used to assess pricing trends and market dynamics.

We use particular data simulation models to get our market estimates and forecasts. These models are developed and tailored to match the unique needs of every study. They are nimble and adaptable. For the most part, we use a joint combination of technological analysis, economic tools, domain experience, and economic techniques to forecast and estimate the market. In general, we favor using a bottom-up method to assess the worldwide market and calculate the anticipated rate of growth.

To verify our hypotheses and the results we have gotten, we carry out in-depth primary interviews, which include phone conversations, in-person discussions, and targeted group discussions. Extensive primary research has been conducted to verify our figures and forecast. These interviews also provide us with an objective view of the market, important information on companies operating in various markets, and up-to-date business scenarios.

Point of Care Diagnostics Market based on Product:
• Blood Glucose Monitoring
• Infectious Disease Testing
• Cardiometabolic Disease Testing
• Pregnancy & Fertility Testing
• Hematology Testing
• Others
Point of Care Diagnostics Market based on Sample:
• Blood
• Nasal and Oropharyngeal Swabs
• Urine
• Others
Point of Care Diagnostics Market based on End User:
• Hospital Bedside
• Physician’s Office Lab
• Urgent Care & Retail Clinics
• Home & Self testing
Point of Care Diagnostics Market based on Geography:
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
Real-time and on-site testing for diabetes has been made possible by technology improvements, which has also aided this market segment. The precision and effectiveness of glucose testing at the point of care have improved thanks to these advancements. Furthermore, the growing demand for these goods has been fueled by the growing popularity of wearable and portable glucose meters. These gadgets are appealing choices for both patients and healthcare professionals because of their quick outcomes, simplicity of use, and reduced operating costs.

The market's revenue share was controlled by the clinics sector. This is explained by the growing number of PoC diagnostics laboratory centers opening up within clinics, which has enhanced patient-centered treatment while cutting expenses. Better patient outcomes have resulted from the decentralization of healthcare services brought about by these specialized centers.

Testing operations in hospitals are increasingly being outsourced, which improves test efficiency and lowers personnel expenses. Hospitals use outside resources to complete some diagnostic tests so they can concentrate on their primary duties and optimize their operations. Positive regulations like those found in the CHIP Reauthorization Act and Medicare have also helped the PoC diagnostics industry sector expand. These regulations have produced a favorable atmosphere for implementing and growing PoC testing in various healthcare settings.

Over the course of the projection period, the residential category has grown at the fastest rate. This is explained by the growing use of PoC testing in older and pediatric populations. The geriatric population is expanding and raising life expectancy as a result of lower birth rates in emerging nations and easier access to healthcare. As a result, chronic illnesses like diabetes, memory loss, and heart problems linked to lifestyle choices are more common. PoC testing at home provides these people with accessibility and convenience, which fuels the expansion of the market.

• This report illustrates the most vital attributes of the Point of Care Diagnostics Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Point of Care Diagnostics Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Point of Care Diagnostics Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Point of Care Diagnostics Market.

ページTOPに戻る

Table of Contents

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Product: Market Size & Analysis
5.1. Overview
5.2. Blood Glucose Monitoring
5.3. Infectious Disease Testing
5.4. Cardiometabolic Disease Testing
5.5. Pregnancy & Fertility Testing
5.6. Hematology Testing
5.7. Others
6. Sample: Market Size & Analysis
6.1. Overview
6.2. Blood
6.3. Nasal and Oropharyngeal Swabs
6.4. Urine
6.5. Others
7. End User: Market Size & Analysis
7.1. Overview
7.2. Hospital Bedside
7.3. Physician’s Office Lab
7.4. Urgent Care & Retail Clinics
7.5. Home & Self testing
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. CARDINAL HEALTH INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. TRINITY BIOTECH
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. BIO-RAD LABORATORIES INC.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. THERMO FISHER SCIENTIFIC INC.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. QUEST DIAGNOSTICS INCORPORATED
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. QUIDEL CORPORATION
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. ABBOTT LABORATORIES
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. MESA BIOTECH
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. F. HOFFMANN-LA ROCHE LTD
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. CEPHEID
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy

11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. POINT OF CARE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR BLOOD GLUCOSE MONITORING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR INFECTIOUS DISEASE TESTING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR CARDIOMETABOLIC DISEASE TESTING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR PREGNANCY & FERTILITY TESTING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR HEMATOLOGY TESTING, 2021-2030 (USD BILLION)
TABLE 7. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. POINT OF CARE DIAGNOSTICS MARKET VALUE, BY SAMPLE, 2021-2030 (USD BILLION)
TABLE 9. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR BLOOD, 2021-2030 (USD BILLION)
TABLE 10. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR NASAL AND OROPHARYNGEAL SWABS, 2021-2030 (USD BILLION)
TABLE 11. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR URINE, 2021-2030 (USD BILLION)
TABLE 12. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. POINT OF CARE DIAGNOSTICS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 14. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR HOSPITAL BEDSIDE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 15. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR PHYSICIAN’S OFFICE LAB, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR URGENT CARE & RETAIL CLINICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 17. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR HOME & SELF TESTING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 19. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 20. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 21. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 22. U.S POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 23. U.S POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 24. U.S POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 25. U.S POINT OF CARE DIAGNOSTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 26. CANADA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 27. CANADA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 28. CANADA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 29. MEXICO POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 30. MEXICO POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 31. MEXICO POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 32. EUROPE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 33. EUROPE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 34. EUROPE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 35. EUROPE POINT OF CARE DIAGNOSTICS MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION)
TABLE 36. GERMANY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 37. GERMANY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 38. GERMANY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 39. U.K POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 40. U.K POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 41. U.K POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 42. FRANCE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 43. FRANCE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 44. FRANCE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 45. ITALY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 46. ITALY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 47. ITALY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 48. SPAIN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 49. SPAIN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 50. SPAIN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 51. ROE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 52. ROE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 53. ROE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 54. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 55. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 56. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 57. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 58. CHINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 59. CHINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 60. CHINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 61. INDIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 62. INDIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 63. INDIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 64. JAPAN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 65. JAPAN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 66. JAPAN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 67. REST OF APAC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 68. REST OF APAC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 69. REST OF APAC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 70. LATIN AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 71. LATIN AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 72. LATIN AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 73. BRAZIL POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 74. BRAZIL POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 75. BRAZIL POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 76. ARGENTINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 77. ARGENTINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 78. ARGENTINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 79. MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 80. MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 81. MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 82. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 83. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 84. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 85. UAE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 86. UAE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 87. UAE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 88. REST OF MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 89. REST OF MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 90. REST OF MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 91. CARDINAL HEALTH INC.: FINANCIALS
TABLE 92. CARDINAL HEALTH INC.: PRODUCTS & SERVICES
TABLE 93. CARDINAL HEALTH INC.: RECENT DEVELOPMENTS
TABLE 94. TRINITY BIOTECH: FINANCIALS
TABLE 95. TRINITY BIOTECH: PRODUCTS & SERVICES
TABLE 96. TRINITY BIOTECH: RECENT DEVELOPMENTS
TABLE 97. BIO-RAD LABORATORIES INC.: FINANCIALS
TABLE 98. BIO-RAD LABORATORIES INC.: PRODUCTS & SERVICES
TABLE 99. BIO-RAD LABORATORIES INC.: RECENT DEVELOPMENTS
TABLE 100. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
TABLE 101. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
TABLE 102. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
TABLE 103. QUEST DIAGNOSTICS INCORPORATED: FINANCIALS
TABLE 104. QUEST DIAGNOSTICS INCORPORATED: PRODUCTS & SERVICES
TABLE 105. QUEST DIAGNOSTICS INCORPORATED: RECENT DEVELOPMENTS
TABLE 106. QUIDEL CORPORATION: FINANCIALS
TABLE 107. QUIDEL CORPORATION: PRODUCTS & SERVICES
TABLE 108. QUIDEL CORPORATION: RECENT DEVELOPMENTS
TABLE 109. ABBOTT LABORATORIES: FINANCIALS
TABLE 110. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 111. ABBOTT LABORATORIES: DEVELOPMENTS
TABLE 112. MESA BIOTECH: FINANCIALS
TABLE 113. MESA BIOTECH: PRODUCTS & SERVICES
TABLE 114. MESA BIOTECH: RECENT DEVELOPMENTS
TABLE 115. F. HOFFMANN-LA ROCHE LTD: FINANCIALS
TABLE 116. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 117. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 118. CEPHEID: FINANCIALS
TABLE 119. CEPHEID: PRODUCTS & SERVICES
TABLE 120. CEPHEID: RECENT DEVELOPMENTS